Phosphotyrosyl-based motifs in the structure-based design of protein-tyrosine kinase-dependent signal transduction inhibitors

Current Pharmaceutical Design

Volumn 3, Issue 3, 1997, Pages 291-304

  Burke Jr , Terrence R ^a   Yao, Zhu Jun ^b   Smyth, Mark S ^b   Ye, Bin ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG DESIGN; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 16944366605     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Edwards, D. R. Trends Pharmacol. Sci. 1994, 15, 239-244.
2. Karin, M.; Hunter, T. Curr. Biol. 1995, 5, 747-757.
3. Boulikas, T. Int. J. Oncol. 1995, 6, 271-278.
4. Chan, A. C.; Desai, D. M.; Weiss, A. Ann. Rev. Immunol. 1994, 12, 555-592.
5. Zenner, G.; Zurhausen, J. D.; Burn, P.; Mustelin, T. Bioessays 1995, 17, 967-975.
6. Brugge, J. S. Science 1993, 260, 918-919.
7. Coombes, R. C. Mol. Aspects Med. 1994, 14, 373-449.
8. Henderson, B.; Poole, S. Adv. Pharmacol. 1994, 25, 53-115.
9. Powis, G. Tumori 1994, 80, 69-87.
10. Powis, G.; Workman, P. Anti-Cancer Drug Des. 1994, 9, 263-277.
11. Rosen, J.; Day, A.; Jones, T. K.; Turner-Jones, E. T.; Nadzan, A. M.; Stein, R. B. J. Med. Chem. 1995, 38, 4855-4874.
12. Levitzki, A. Curr. Opin. Cell Biol. 1996, 8, 239-244.
13. Patrick, D. R.; Heimbrook, D. C. Drug Discov. Today 1996, 1, 325-330.
14. Saltiel, A. R.; Sawyer, T. K. Chem. Biol. 1996, 3, 887-893.
15. Fantl, W. J.; Johnson, D. E.; Williams, L. T. Ann. Rev. Biochem. 1993, 453-481.